A brand new approach to cancer treatments – immunotherapy

Source: TMU Wanfang Hospital

Published on 2020-04-30

With the incidence and mortality rate of cancer steadily growing globally, the refinement and advancement of cancer treatment has become a medical issue that brooks no delay in the modern society.


Late stage cancer often involves metastasis of the cancer to distant organs, and in the past, such tumors cannot be surgically removed, thus there is a reliance of treatment by drugs. The development history of cancer treatment can be largely divided into three phases:

  1. The foundation phase from the 1980s, over a twenty-year period where chemotherapy was the mainstay treatment.
  2. The refinement phase since 2000, where specific markers on cancer cells are used to develop target therapy.
  3. The breakthrough phase since 2015, where cancer treatment has entered a brand new era known as immunotherapy

Dr. Ming-Hung Hu from the Department of Hematology and Oncology, Wanfang Hospital

The main target for traditional chemotherapy treatment is all the cells in the human body, and suppresses biological signals required for cellular growth in order to achieve the effect of reducing the number of cancer cells. Although chemotherapy can achieve good results, the process also effect the functioning of normal, healthy cells in the body, often leading to severe side effects, such as nausea, vomiting, hair loss or reduced white blood cell counts.

Immunotherapy differs from chemotherapy as it does not directly affect tumor cells, but rather “regulate” the existing immune cells in the human body in different ways to eliminate cancer cells. The human immune system is a natural defense mechanism, able to eliminate harmful external agents such as viruses and bacteria, while also fighting against cancer cells that arose through mutations in the body. Under normal circumstances, T-cells in the body can distinguish the tumor antigens presented on cancer cells, and T-cells that successfully identify these cancer cells can destroy them through a series of immune responses. Currently, the most commonly seen immunotherapy drugs is responsible for “waking up” these immune cells, so that the best defense force of the human body can constantly attack and eliminate these lethal tumor cells.

Cancer vaccine as oncology therapy and disease treatment concept using immunotherapy with cells from the human body as a 3D illustration. Photo Credit: Shutterstock

TMU Study Abroad Info Session

Download the slides for getting more information about the study abroad opportunities in TMU

TMU International Outstanding Alumni-Usman Iqbal

People are always thinking about where everyone else is going. They don’t consider that smaller countries can also have good quality education.—Dr. Usman Iqbal

TMU PhD Student Fang-Chi Hsu Went to Johns Hopkins University for a Year of Research upon Receiving a Subsidy Provided by the Ministry of Science and Technology

Encouraged by teachers and classmates, Fang-Chi Hsu, a PhD Student of the PhD Program for Transcriptional Medicine of the College of Medical Science and Technology, Taipei Medical University, departed for Sidney Kimmel Comprehensive Cancer Center (SKCCC) of Johns Hopkins University (JHU) in 2020 for a year of research upon receiving a subsidy through the Graduate Student Study Abroad Program provided by the Ministry of Science and Technology.

TMU special digital mini-exhibition cultivates future generations of talents

Taipei Medical University and National Palace Museum jointly held the National Palace Museum X TMU Pop Up Exhibition special series of digital mini-exhibitions at the end of December 2019 on the University campus.

RISE worldwide 2021

In this program research groups, laboratories and doctoral students can apply to host a motivated and wellqualified student from Germany.

Taipei Medical University spin-out company launches “ASKiN”, providing an online dermatologist consultation platform accessible through the LINE App

DermAI Co., Ltd., a Taipei Medical University spin-out, has launched the online dermatologist consultation platform “ASKiN.”